Riassunto
Il concetto di qualità, e specificamente di qualità in sanità, è molto ampio e spesso assume connotati diversi in funzione dell’ottica con cui si osserva il fenomeno.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Bibliografia
Donabedian A (1980) The definition of quality and approaches to its assessment. Health Administration Press, Ann Arbor (ed. it. La qualità dell’assistenza sanitaria. Nuova Italia Scientifica, Roma 1989)
EuNetHTA project: Overview of results http://www.eunethta.net/Public/Work_Packages/EUnetHTAProject-2006-08/EUnetHTA_Deliverables_project_2006-2008/
Canadian Agency for Drugs and Technologies in Health (2006) Guidelines for the Economic Evaluation of Health Technologies, 3rd edition. CADTH, Ottawa
Cicchetti A, Marchetti M (a cura di) (2010) Manuale di Health Technology Assessment. Il Pensiero Scientifico, Roma
Salvatori M, Oradei M (2010) Economic evaluation of nuclear medicine procedures. Eur J Nucl Med Mol Imaging 37:1786–1792
Mohan HK, Miles KA (2009) Cost-effectiveness of 99mTc-sestamibi in predicting response to chemotherapy in patients with lung cancer: systematic review and meta-analysis. J Nucl Med. 50:376–381
International Network of Agencies for Health Technology Assessment (INAHTA) HTA Resources http://inahta.episerverhotell.net/HTA/
Pearson SD, Rawlins (2005) Quality, innovation, and value for money. NICE and the British National Health Service. JAMA 294:2618–22
SIFE — Società italiana di farmacoeconomia (1999) Linee guida per la conduzione di studi sull’efficacia e sul costo dei trattamenti farmacologici (ver. 1.1 — 11/99). Giornale Italiano di Farmacoeconomia 3:147–153
The Italian Group of Pharmacoeconomic Studies (2001) Guidelines for economic valuations in Italy: Recommendations from the italian group of pharmacoeconomic studies. Drug Information Journal 35:189–201
Simbula S, Burchini G, Santarlasci B et al (2008) Rassegna degli studi di costo-efficacia relativi ad interventi terapeutici o preventivi “not enough value for money”. Giornale Italiano di Farmacia Clinica 22:1–20
Briggs AH, Gray AM (1993) Handling uncertainty when performing economic evaluation of health care intervention. Health Technology Assessment 3:1–134
Barber JA, Thompson SG (1998) Analysis and interpretation of cost data in randomised controlled trials: review of published studies. BMJ 317:1195–1200
Russell LB, Gold MR, Siegel JE et al (1996) The role of cost-effectiveness analysis in health and medicine. Panel on cost-effectiveness in health and medicine. JAMA 276:1172–1177
Siegel JE, Weinstein MC, Russell LB, Gold MR (1996) Recommendations for reporting cost-effectiveness analysis. JAMA 276:1339–1341
Riassunto delle caratteristiche del prodotto (Mabthera, Rituximab) http://antineoplastici.agenziafarmaco.it/normativa_registro_trast.htm
Riassunto delle caratteristiche del prodotto (Zevalin, Ibritumomab Tiuxetano) http://antineoplastici.agenziafarmaco.it/normativa_registro_trast.htm
Witzig TE, Gordon LI, Cabanillas F, Cabanillas F et al (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 20:2453–2463
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag Italia
About this chapter
Cite this chapter
Oradei, M., Di Turi, R. (2011). Health technology assessment e farmacoeconomia: strumenti per la qualità dei radiofarmaci. In: La qualità nella preparazione dei radiofarmaci. Imaging & formazione, vol 6. Springer, Milano. https://doi.org/10.1007/978-88-470-2020-7_3
Download citation
DOI: https://doi.org/10.1007/978-88-470-2020-7_3
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-2019-1
Online ISBN: 978-88-470-2020-7
eBook Packages: MedicineMedicine (R0)